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Abstract
Background: Re-irradiation (re-RT) of the thorax is challenging due to the impact of prior therapies on normal
tissues, and there are few reports of definitive re-RT. The treatment toxicities and efficacy of re-RT are not well
known. The aim of the present study was to assess the safety and efficacy of definitive re-RT of the thorax.
Methods: Patients who were treated with thoracic re-RT between March 2007 and December 2014 were
retrospectively analyzed. Primary and re-irradiation plans were required to have an overlap of dose distributions for
the 80 % isodose level. All doses were recalculated to an equivalent dose of 2 Gy per fraction (EQD2). When
possible, analysis of dose accumulation was carried out using the medical image merge (MIM) (®) software program
(version 6.5, MIM Software Inc., Cleveland, OH). Administration dosages for organs at risk were defined.
Results: Fourteen (67 %) and seven (33 %) patients with non-small cell carcinoma (NSCLC) and small cell carcinoma
(SCLC), respectively, were identified. The patients’ median age was 72 (range 53–85) years. Fifteen patients (71 %)
had “proximal” tumors, defined as tumors at the distal 2 cm of the trachea, carina, and main bronchi. The median
interval from initial RT to re-RT was 26.8 (range 11.4–92.3) months. Re-RT was delivered by X-ray beam and proton
beam therapy in 20 (95 %) patients and 1 (5 %) patient, respectively. The median radiation dose of re-RT was 60
(range 54–87.5) Gy10 and 50 (range 50.0–87.5) Gy10 for patients with NSCLC and SCLC, respectively. Grade 3 acute
radiation pneumonitis occurred in only one patient. There were no other serious complications. The median
follow-up time was 22.1 (range 2.3–56.4) months. The median local progression-free survival time (LPFS) and overall
survival time (OS) were 12.9 (95 % confidence interval (CI): 8.9–27.9) months and 31.4 (95 % CI: 16.9–45.9) months,
respectively. Patients receiving≥ 60 Gy10 at re-RT had longer LPFS (p = 0.04).
Conclusions: Good safety with longer OS than in previous reports was demonstrated. Re-RT seems to be a
promising treatment option. Further study to define the risk-benefit ratios is necessary.
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Background
Lung cancer remains one of the most prevalent and
deadliest malignancies worldwide, accounting for around
1.8 million deaths each year [1]. External beam radiation
therapy (RT) plays an important role in curative
management strategies for both small cell lung cancer
(SCLC) and non-small cell lung cancer (NSCLC) [2–6].
In NSCLC patients treated with concurrent chemoradia-
tion to the thorax, 5-year rates of locoregional recur-
rence approach 30 % [7]. In SCLC patients, locoregional
recurrence occurred in 36 % of patients [8]. Disease re-
currence is still the dominant cause of death after initial
treatment.
Second-line chemotherapy is usually selected even
when no distant metastasis is observed. For patients with
NSCLC and SCLC, progression-free survival (PFS) is 2–
8.5 months and 3.3–3.7 months, and median overall
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survival (OS) is 5.6–11.5 months and 5.5–6.4 months,
respectively [9–17].
Re-irradiation (re-RT) has not been considered first-
choice, because high-dose re-RT might cause severe ra-
diation injury. Since Green et al reported the efficacy
and safety of re-RT as definitive therapy for intrathoracic
disease [18], several studies of re-RT have been reported.
However, there are few reports of re-RT with curative
intent [19–32]. Additionally, there are few detailed re-
ports about the total dose of initial RT and re-RT for
each organ at risk [23–28]. Furthermore, due to the
characteristics of recurrent disease, long-term observa-
tion of treatment results is difficult. The efficacy and
safety of re-RT are unclear. Thus, our institutional ex-
perience was retrospectively analyzed to investigate the
clinical outcomes, including survival and toxicities.
Methods
This study was approved by the institutional review
board of Shizuoka Cancer Center. Medical records were
retrospectively obtained. Patients who were registered in
the Radiology Information System in Shizuoka Cancer
Center between September 2002 and December 2014
were identified. Patients who fulfilled the following cri-
teria were included: (1) the location of the primary
tumor was “lung” or “trachea”; (2) recurrences were con-
firmed by evidence seen on computerized tomography
(CT) and/or positron emission tomography (PET) show-
ing the reappearance or enlargement of the tumor
shadow within the previous irradiated volume; (3) the
patient received external beam radiotherapy to the chest
at least twice; (4) the patient was administered at least
45 Gy each time; (5) there was overlap of the two separ-
ate dose distributions for the 80 % dose level each time;
and (6) there was no evidence of active metastasis at
re-RT.
Records were reviewed for patient and disease char-
acteristics, prior fractionated radiotherapy dosimetric
parameters, re-RT dosimetric parameters, toxicities,
treatment response, local progression-free survival
(LPFS), PFS, and OS. Tumors were re-staged using the
Union for International Cancer Control TNM Classifi-
cation of Malignant Tumors 7th edition (UICC 7th).
Previous radiotherapy and re-RT variables reviewed in-
cluded dates of therapy, prescription dose, graphic dose
distributions, planning target volume (PTV) size, and
tumor location. The treated part was defined as follows:
“proximal” was defined as the distal 2 cm of the trachea,
the carina, and the right and left main bronchi. Analysis
of dose accumulation was carried out after rigid regis-
tration using the medical image merge (MIM) (®)
software program (version 6.5, MIM Software Inc.,
Cleveland, OH), if data were available. All doses were
recalculated to an equivalent dose of 2 Gy per fraction
(EQD2) with the formula: d*n*((d + α/β)/(2 + α/β)), with
d the dose per fraction (Gy) and n the number of frac-
tions. For tumor dose and acute side effects, an α/β
value of 10 Gy was used (Gy10), and for late effects, an
Fig. 1 Patient selection and exclusion criteria
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α/β value of 3 Gy was used (Gy3) [28]. The administra-
tion dosage for organs at risk was defined according to
the Radiation Therapy Oncology Group (RTOG) con-
touring atlas of lung (https://www.rtog.org/CoreLab/
ContouringAtlases/LungAtlas.aspx). The severities of
acute (within 30 days of ending radiation) and late tox-
icities were evaluated according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) version
4.0. Treatment response was evaluated according to the
response evaluation criteria in solid tumors (RECIST)
version 1.1. OS was defined as the interval between the
index date and the date of death or censored on the last
date of confirmed survival, whichever came first. LPFS
and PFS were calculated from the index date to the
earliest date of local failure and systemic failure or
death, whichever came first. Local failure was defined as
recurrence within the re-RT site. The index date was the
first day of re-RT. The survival curves were calculated
using the Kaplan-Meier method, and the differences
between the curves were analyzed using the log-rank
test. A univariate significance level of P < 0.05 was used
for identifying predictors.
Results
Forty-two patients were found to have received re-RT
within the previous irradiation volume. Twenty-one
patients were excluded; the reasons for exclusion are
shown in Fig. 1. Finally, 14 patients (67 %) with NSCLC
and seven patients (33 %) with SCLC who received re-
RT were identified. Informed consent was obtained from
all patients at the time of re-RT.
Patient and disease characteristics at re-RT are shown
in Table 1. The median age was 72 years (range 53–85
years). All patients except one had Eastern Cooperative
Oncology Group (ECOG) performance status (PS) 0–1.
The median interval between the end of initial RT and
recurrence was 26.0 months (range 7.0–87.8 months).
Recurrence was documented pathologically in only two
cases (11 %), and their results were the same as the ini-
tial pathology. The majority of tumor recurrence (85 %)
occurred at the original tumor site. Fifteen patients
(71 %) had proximal recurrent tumor. One patient had
stage IV disease at initial RT. He had surgery as initial
treatment. He then developed solitary brain metastasis
and local tumor recurrence. For both lesions, local
radiotherapy appeared to offer the possibility of rad-
ical cure.
Initial and re-RT treatment details are shown in
Table 2. The median interval from initial RT to re-RT
was 26.8 months (range 11.4–92.3 months). At the time
of initial RT, the median radiation dose was 60 Gy10
(range 51.8–87.5 Gy10) for NSCLC patients, while each
SCLC patient received 43.1 Gy10. Radiotherapy was
delivered by X-ray beam therapy in 20 patients (95 %).
Only one (5 %) patient with stage IA (UICC 7th) NSCLC
refused surgery and was treated using proton beam ther-
apy. He had proximal tumor and chronic heart failure.
Proton beam therapy had the advantage of avoiding or-
gans at risk, including the heart. In addition, avoiding
organs at risk led to an increased prescription dose.
Concurrent chemotherapy was delivered in 16 (76 %)
patients. At the time of re-RT, the median radiation dose
was 60 Gy10 (range 54–87.5 Gy10) for NSCLC patients
and 50 Gy10 (range 50–87.5 Gy10) for SCLC patients.
Radiotherapy was delivered by X-ray beam therapy in 19
patients (90 %) and by proton beam therapy in 2 patients
(10 %). Only one patient (5 %) was administered concur-
rent chemotherapy. The median PTV volume was
57.4 cc (range 7–601.7 cc). Prior radiotherapy and re-RT
details are listed in Table 2.
Dose distributions of initial RT and re-RT were accu-
mulated for 13 patients with NSCLC and 5 patients with





Median age at re-RT, years (range) 72 (53–85)
ECOG PS, n (%)
0–1 20 (95)
2 1 (5)
Histology at primary RT, n (%)
NSCLC 14 (67)




Clinical Stage at primary RT, n (%)
IA / B 4 (19)
IIA / B 4 (19)
IIIA/ B 12 (57)
IV 1 (5)
Pattern of recurrence, n (%)
Primary tumor 15 (71)
Initially existent metastatic LN (± primary tumor) 3 (14)
Intrapulmonary new lesion 1 (5)
Regional LN new lesion 1 (5)
Both intrapulmonary and regional LN new region 1 (5)
Irradiation tumor location, n (%)
Proximal 15 (71)
Peripheral 6 (29)
re-RT re-irradiation, PS performance status, primary RT primary radiotherapy,
NSCLC Non small cell lung cancer, SCLC Small cell lung cancer, LN lymph node
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SCLC. The median cumulative maximum dose of the
lung was 130 Gy3. The median percentage of total lung
volume receiving a cumulative dose of 20 Gy3 (V20) was
17 % (range 5–34 %). The mean total lung dose was
12 Gy3. The median cumulative dosage that was irradi-
ated to a 1 cc volume and the mean irradiated volume of
the organs at risk are shown in Table 3. Four patients re-
ceived a cumulative dosage of over 50 Gy3 to a 1 cc
volume.
The most frequent acute toxicity reported was Grade
1–2 radiation dermatitis. No ≥Grade 3 acute and late
toxicities were observed, except in one patient with
grade 3 acute pneumonitis that was suspected to be
radiotherapy-induced (radiation pneumonitis) (Table 4).
Grade 1–2 late pulmonary toxicity was observed in 9 pa-
tients (52 %), but there were no serious complications.
At the time of analysis, 6 patients were alive. The me-
dian follow-up time was 22.1 months (range 2.3–
56.4 months). The responses to re-RT were complete re-
sponse (CR) in 4 patients (19 %) and partial response
(PR) in 5 patients (24 %). Disease progression after re-
RT was observed in 14 patients (67 %). The first failure
after re-RT occurred in the field of re-RT in 10 patients
(71 %), including 2 patients who had both in and out of
field recurrence. Chemotherapy after disease progression
was administered to 5 patients (24 %). Among them,
three patients had NSCLC, and two patients had SCLC.
The median PFS was 10.9 months (95 % confidence
interval (CI): 6.8–27.9 months). The median LPFS was
12.9 months (95 % CI: 8.9–27.9 months). The 1-year and
2-year LPFS rates were 57 % and 34 %, respectively
Table 3 Dose distribution of initial RT and re-RT
Initial Re-irradiation Total
Lung dose volume (%)
V5
Ipsilateral lung 43 32 55
Contralateral lung 6 0.5 11
Total lung 22 16 30
V20
Ipsilateral lung 32 15 38
Contralateral lung 2 0 3
Total lung 14 7 17
Mean dose, Gy3
Ipsilateral lung 17 10 25
Contralateral lung 1 1 3
Total lung 8 5 12
Heart 3 7 5
Total median dose, Gy3 D1cc D10cc
Spinal cord 32 25
Esophagus 42 33
Aorta 87 65





Spinal cord ≥40 Gy3 0.3
Spinal cord ≥50 Gy3 0
Heart ≥70 Gy3 0
Esophagus ≥70 Gy3 5
Aorta ≥70 Gy3 7
Pulmonary artery ≥70 Gy3 4
V5 (20) The percentage of lung receiving 5 (20) Gy3 or more, OAR organ at risk,
D1 (10) cc the dosage irradiated to a 1 (10) cc volume
Table 4 Toxicity
Grade 1-2 Grade 3 Grade 4
Acute toxicities, n
Radiation dermatitis 9 0 0
Esophagitis 4 0 0
Pneumonitis 3 1 0
Anorexia 3 0 0
Malaise 2 - -
Late toxicities, n
Pneumonitis 9 0 0
Chest wall pain 1 0 -
Pruritus 1 0 -
Table 2 Overview of the initial RT and re-RT details
Median interval to re-RT, months (range) 26.8 (11.4–92.3)
Initial radiation Re-irradiation
Median RT dose, Gy10 (range)
NSCLC 60 (51.8–87.5) 60 (54–87.5)
SCLC 43.1 all patients 50 (50–87.5)
Radiation technique, n (%)
Conventional fractionation 10 (48) 13 (62)
Hyperfractionation 8 (38) 0 (0)
Hypofractionation 3 (14) 8 (38)
Radiation delivery, n (%)
Photon therapy 20 (95) 19 (90)
Proton therapy 1 (5) 2 (10)
Concurrent chemotherapy, n (%)
Yes 16 (76) 1 (5)
No 5 (24) 20 (95)
Median PTV, cc (range) 57.4 (7–601.7)
RT radiotherapy, NSCLC Non small cell lung cancer, SCLC Small cell lung
cancer, PTV planning target volume
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(Fig. 2). The median OS was 31.4 months (95 % CI:
16.9–45.9 months). The 1-year and 2-year OS rates were
76 % and 64 %, respectively (Fig. 3).
On univariate analysis, PTV < 75 cc was associated with
longer OS (p = 0.03), and patients receiving ≥ 60 Gy10 at
re-RT had longer LPFS (p = 0.04). There were no signifi-
cant differences in OS and LPFS with any other factors.
The median OS with or without subsequent chemother-
apy was 37.4 months and 31.4 months, respectively; there
was no significant difference (P = 0.57) (Table 5).
Discussion
The outcomes of 21 patients given re-RT for recurrent
tumors of the thorax were reviewed. There was some
therapeutic efficacy with a median follow-up time of
22.1 months and median OS of 31.4 months. To the best
of our knowledge, this study had longer follow-up and
the best survival outcomes compared with any previous
reports regarding re-RT for recurrent lung cancer. In
the present study, PTV volume was significantly associ-
ated with OS. Reyngold et al. also reported that PTV
volume <75 cc was significantly associated with longer
OS [29]. The present patients had a generally small
PTV. As size increases, the tumor becomes more
radiation-resistant due to the presence of hypoxic cells.
The generally smaller PTV might have had an impact
on both LPFS and OS. It was not possible to identify
any other factors significantly associated with OS. How-
ever, the good OS might be explained by patient selec-
tion. In our institution, we discuss the indications for
Fig. 2 Kaplan-Meier curve of local progression-free survival for all patients
Fig. 3 Kaplan-Meier curve of overall survival for all patients
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treatment within a cancer board consisting of thoracic
surgeons, thoracic physicians, radiation oncologists, and
radiologists. All patients had good ECOG PS of 0-1. The
median interval between initial RT and re-RT was
25 months, and all patients except one had an interval
over 1 year. Despite a median interval of over 2 years,
the majority of tumor recurrence occurred at the ori-
ginal tumor site, with no widening to new regional
lymph nodes. This suggests the possibility that the im-
provement of OS reflected tumors with slow growth
and spread. Small PTV volume [29] and long treatment
interval [30, 31] are each reported as factors signifi-
cantly associated with longer OS. This supports the
present considerations. Finally, when the present OS is
compared with previous reports, with advancing diag-
nostic technology, it is possible that patients with mi-
nute metastases were excluded. In contrast, the median
LPFS was not as good as OS. An explanation for this is
that the median OS in previous reports was generally
poor. There is a possibility that they could not observe
recurrence over a sufficient time period in the previous
reports. The present result may also reflect longer
follow-up. Thus, this does not imply that treatment effi-
cacy was poor. However, receiving a dose over 60 Gy10
was significantly associated with longer LPFS. In
addition, De Bari et al. also reported that outcome re-
sults of re-RT with stereotactic ablative radiotherapy ap-
pear superior to those achievable with conventional
radiotherapy and/or chemoradiotherapy [22]. Dose es-
calation needs to be considered.
Grade 3 acute radiation pneumonitis occurred in only
one patient. There were no other serious complications.
The present results suggest the safety of re-RT over a
long period. In addition, it is important that tumor loca-
tion be reviewed when we think about the safety of
radiotherapy to the lung. It has been proposed that the
risk of irradiation is greater to centrally located lung tu-
mors even in primary treatment [33]. In the situation of
re-RT, this risk may increase. In fact, Trovo et al., Kil-
burn et al., and Paulen et al. reported fatal toxicity of re-
RT for centrally located tumors [22–24, 32]. The present
study included centrally located tumors in two-thirds of
patients. Despite this, excellent safety was seen with
long-term observation. The explanations for the good
safety may be as follows. First, the patients had a long
interval between primary RT and re-RT. This may con-
tribute to organ repair [34]. Next, the present patients
had a generally small PTV volume, which contributed to
small irradiation field size. Third, the proportion of pa-
tients receiving 2 Gy per fraction was high. This contrib-
uted to lower summed EQD2. However, De Ruysscher et
al. reported that the incidence of severe lung toxic ef-
fects did not differ greatly in patients treated with con-
ventional 3D conformal radiotherapy compared with
patients treated with SABR [20]. One of the reasons for
this is that the choice of the treatment in studies that
they reviewed may have depended on tumor location. Fi-
nally, priority was given to avoiding including the spinal
cord and esophagus in the irradiation field.
Although patient selection may be required, good OS
and safety of re-RT to the thorax were reported. This is
beneficial in offering a treatment option to patients with
recurrent thoracic tumors. A future problem is to define
the risk-benefit ratios with dose escalation.
The present study has several limitations. First, this
study was a single-institution, retrospective study. Sec-
ond, re-RT was not compared with other treatment







Male 15 12.9 0.86 31.4 0.12
Female 6 12.4 43.0
Age, years
≥ 75 9 13.9 0.96 37.3 0.97
< 75 12 10.9 31.4
Interval between end of
initial RT and recurrence,
months
≥ 24 11 13.8 0.66 31.4 0.48
< 24 10 10.9 31.0
Interval between initial RT
and re-RT, months
≥ 24 11 13.8 0.66 31.4 0.48
< 24 10 10.9 31.0
Re-RT dose, Gy10
≥ 60 16 18.2 0.04 37.4 0.41
< 60 5 6.8 22.1
PTV size, cc
> 75 8 12.9 0.78 16.9 0.03
≤ 75 13 13.8 43.5
Pathology
NSCLC 14 13.9 0.88 31.4 0.56
SCLC 7 10.9 37.5
Location
Proximal 15 2.8 0.62 22.1 0.99
Peripheral 6 18.2 37.4
Further chemotherapy
after re-RT
Yes 5 37.4 0.57
No 9 31.4
RT radiotherapy, re-RT re-irradiation, NSCLC Non small cell lung cancer, SCLC Small
cell lung cancer, PTV planning target volume; Bold values represent statistically
significant factors
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options for patients with locally recurrent tumor. It is
unclear whether re-RT is the optimal treatment for these
patients. Third, the number of patients was small, which
may explain why statistical significance was not reached.
Finally, interval time contributing to the effect of dosage
was not considered when the prior and re-RT doses
were estimated. When we use the therapeutic procedure
in patients with a shorter interval between primary RT
and re-RT, attention should be paid to treatment safety,
since this has not been established for such patients.
Conclusions
Re-RT to the thorax for recurrent tumor seems to be a
promising and safe treatment option even in patients
with proximal tumor. However, local control was not
satisfactory. With carefully selected indications, further
study is needed to define the optimal treatment dose.
Abbreviations
CI, confidence interval; CR, complete response; CT, computerized
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eastern cooperative oncology group; EQD2, equivalent dose of 2 Gy per
fraction; LN, lymph node; LPFS, local progression-free survival; NSCLC, non small
cell lung cancer; OS, overall survival; PET, positron emission tomography; PFS,
progression-free survival; PR, partial response; PTV, planning target volume;
RECIST, response evaluation criteria in solid tumors; re-RT, re-irradiation; RT,
radiotherapy; RTOG, radiation therapy oncology group; SABR, stereotactic
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